News and Insights

Defining and Demonstrating Value

Prioritizing Evidence Generation For Impact

Across the globe, pharma companies are encountering new levels of price resistance and competitive pressure.  Providing compelling evidence to demonstrate differentiated value has been recognized as key to mitigating these pressures.  However, restrictive regulations threaten to significantly change the financial picture across the industry, such that no functional area will…

Establishing a Research Network to Drive Differentiation in a Dynamic Market

Clinical research networks continue to play a pivotal role in supporting pipeline development.  However, the importance of these networks extends well beyond the conduct of clinical trials.  Clinical investigators can support market conditioning, serve as important levers for informing evidence-based clinical pathways/guidelines, and aid in the generation of real-world evidence…

Is Medicare Price Negotiation the Solution We Need?

Numerof Brief

On August 29th, the Biden Administration named the 10 drugs that will be subject to price negotiation with Medicare in the initial implementation of the Inflation Reduction Act (IRA) of 2022. Release of the list marked a milestone in a decades-long effort by Democrats to use the purchasing power of…

Big Pharma Needs a Better Business Model, Not More Legislation

Forbes

When the Trump administration dropped the drug rebate rule it introduced back in January – a rule that intended to prohibit pharmacy benefit managers (PBMs) from pocketing some of the rebates they should be passing along to patients – the decision sent shockwaves through the healthcare industry, particularly the pharma…

Engaging in Value-Based Contracts with Providers

Pharmaceutical Executive

With spiraling cost inflation and outcomes that lag many other developed economies, the US government’s healthcare insurance authority (CMS), is driving reform aimed at better quality and lower cost, and private payers are following suit. Both state and private payers are moving toward alternative payment models, like value-based payments, that…